Stroke


click here to return to the Clinical Trials page


Ongoing Clinical Trials


CLEAR III
  • Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III (NCT00784134).
  • Eligibility:
    1. Patients ages 18 to 80 with spontaneous intraventricular hemorrhage obstructing 3rd or 4th ventricles
    2. Symptom onset less than 24 hours prior to diagnostic CT scan
    3. Extracranial ventricular drain placed per standard medical care
    4. Clot stability at 6 hours or more following intraventricular catheter placement
    5. Historical Ranking score of 0 or 1
  • Local Principal Investigator: Agnieszka Ardelt MD PhD
  • Study Coordinator: Cedric McKoy APN

MISTIE III
  • Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III (NCT01827046).
  • The MISTIE trial will evaluate blood clot removal using minimally invasive surgery with recombinant tissue plasminogen activator in order to provide information on the relationship between blood clot removal and functional outcome.
  • Eligibility:
    • Patients ages 18 to 80 with spontaneous supratentorial intracerebral hemorrhage
    • Symptoms lasting less than 24 hours prior to diagnostic CT scan
    • Clot size stable on follow-up CT scan after 6 hours
    • Historical Rankin score of 0 or 1
  • Principal Investigator: Issam Awad MD
  • Local Principal Investigator: Agnieszka Ardelt MD PhD
  • Study Coordinator: Agnieszka Stadnik, MS

THERAPY
  • The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke.
  • THERAPY is a randomized trial of endovascular clot retrievl versus standard medical therapy after the administration of IV tPA in patients with large vessel occlusions with clots that are more than 8 mm long.
  • Eligibility:
    • Patients aged 18 to 85 with acute ischemic stroke who are eligible for IV rt-PA therapy
    • Evidence for a large vessel occlusion in the anterior circulation with a clot length of 8 mm or more
    • NIHSS of 8 or more, or aphasic at presentation
  • Local Principal Investigator: Seon-Kyu Lee MD PhD
  • Study Coordinator: Pamela Carter

The NINDS Stroke Trials Network
  • Working with colleagues at academic medical institutions across the Chicago metropolitan area, the University of Chicago Stroke Center has formed the Chicago Stroke Trials Consortium, a regional coordinating center in the National Institutes of Health-sponsored stroke trials network (U10 NS086608).
  • NOT YET ENROLLING
  • Local Principal Investigator: James Brorson MD
  • Study Coordinator: Cedric McKoy APN

Inflammatory and Signaling Pathways in Resected Cerebrovascular Malformations (CVMs)
  • This trial examines biochemical and molecular features of tissue from cerebrovascular malformations resected from patients.
  • Principal Investigator: Issam Awad MD
  • Study Coordinator: Robert Shenkar PhD

ROCK Biomarkers in Blood Lymphocytes from Patients with Cerebral Cavernous Malformations
  • This observational trial examines biomarkers in circulating lyumphocytes from patients with cerebral cavernous malformations.
  • Principal Investigator: Issam Awad MD
  • Study Coordinator: Robert Shenkar PhD

Brain Permeability in Human Cerebral Cavernous Malformation
  • This trial examines vascular permeability in cerebral cavernous malformations using non-invasive MRI scanning technology.
  • Principal Investigator: Issam Awad MD
  • Study Coordinator: Robert Shenkar PhD